- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01652638
PHARMACODYNAMICS ASSESSMENT PRODUCT HEPARIN SODIUM (SUBCUTANEOUSLY) OF THE SWINE 5.000UI/ML OF BLAU FARMACÊUTICA S/A IN HEALTHY SUBJECTS IN COMPARISON OF SODIUM HEPARIN APP PHARMACEUTICALS
The objective of this clinical, randomized, crossover, is to assess the pharmacodynamic profile of the drug Heparin Sodium from swine (intravenously), manufactured and marketed by Laboratory Blau Farmacêutica S/A, compared to the product of Heparin Sodium ® company APP Pharmaceuticals, through the determination of activity of the following markers:
- Anti-FXa;
- Anti-FIIA.
Study Overview
Detailed Description
The pharmacodynamic profile of the drug will be assessed through:
- Reason for Anti-FXa activity / Anti-FIIA;
- TFPI activity.
The aPTT activity marker will be evaluated as an exploratory objective.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Alexandre Frederico, physician
- Phone Number: +55 19 3871-6399
- Email: alexandre@lalclinica.com.br
Study Locations
-
-
-
Valinhos, Brazil, 13276245
- LAL Clínica Pesquisa e Desenvolvimento Ltda.
-
Contact:
- Alexandre Frederico, physician
- Phone Number: +55 19 3871-6399
- Email: alexandre@lalclinica.com.br
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Confirm the voluntary participation and agree to all the purposes of the study by signing and dating the IC in two ways;
- Being male, aged between 18 and 55 years old and clinically healthy;
- BMI ≥ 18.5 and ≤ 30.
Exclusion Criteria:
- Participation in clinical trials in the 12 months preceding the survey;
- Presence of pulmonary diseases, cardiovascular, neurological, endocrine, gastrointestinal, genitourinary or other systems;
- acute illness in the period up to 07 days before the beginning of the study;
- determining Chronic administration of medications, such as hypertension, diabetes or any other that requires continued use of any drug;
- Hemoglobin <13 g / dL;
- Continuous use of oral anticoagulants, platelet inhibitors or anti-inflammatory;
- Use of medications that interact with heparin (see Section 7.8.1);
- history of gastrointestinal bleeding, deep vein thrombosis or pulmonary embolism;
- History of coagulopathy and bleeding diathesis;
- Presence of bruises on physical examination.
- Changes in skin or subcutaneous tissue of the place where the injection is made (eg liposuction in the abdomen).
- absolute platelet count below 100 x 109 / L;
- A history of acute haemorrhage in the last 30 days;
- history of sensitivity to biological products derived from mammalian albumin or any component of the formulation;
a) history of allergy or major disease Steven Johnson; p) History of present use or there are at least 12 months of tobacco; q) current or previous history (less than 12 months) of illicit drug use;
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group A
First periody: Test Drug (Heparin Blau Farmacêutica S/A) Secundy periody: Comparator Drug (Heparin APP Pharmaceuticals) |
Whereas it will be a crossover study with two periods, each drug will be administered only once, at a dose of 5.000UI.
In each period, the drug will be administered subcutaneously.
Other Names:
|
Experimental: Group B
First periody: Comparator Drug (Heparin APP Pharmaceuticals) Secundy periody: Test Drug (heparin Blau Farmacêutica S/A) |
Whereas it will be a crossover study with two periods, each drug will be administered only once, at a dose of 5.000UI.
In each period, the drug will be administered subcutaneously.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacodynamic of activity of markers: Anti-Fxa and Anti-FIIA.
Time Frame: 0:20, 0:10 before administration and 0:10, 0:20, 0:30, 0:45, 1, 1:30, 2, 2:30, 3, 3:30, 4, 4:30 , 5, 6, 8, 12 and 24 hours after drug administration.
|
Blood sample
|
0:20, 0:10 before administration and 0:10, 0:20, 0:30, 0:45, 1, 1:30, 2, 2:30, 3, 3:30, 4, 4:30 , 5, 6, 8, 12 and 24 hours after drug administration.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacodynamic of the ratio between the activity Anti-FXa/Anti-FIIa and the activity of TFPI.
Time Frame: TFPI: 0:20, 0:10 before administration and 0:10, 0:20, 0:30, 0:45, 1, 1:30, 2, 2:30, 3, 3:30, 4, 4:30 , 5, 6, 8, 12 and 24 hours after drug administration.
|
Blood sample
|
TFPI: 0:20, 0:10 before administration and 0:10, 0:20, 0:30, 0:45, 1, 1:30, 2, 2:30, 3, 3:30, 4, 4:30 , 5, 6, 8, 12 and 24 hours after drug administration.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HEPBLA0312SC-I
- Version 01 15/03/2012
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Heparin
-
San Filippo Neri General HospitalUniversity of Roma La SapienzaUnknownAngina, Unstable | Stable Angina | Non-ST Elevation (NSTEMI) Myocardial InfarctionItaly
-
Robert F. JamesIndiana University School of MedicineSuspendedNeurobehavioral Manifestations | Aneurysmal Subarachnoid Hemorrhage | Vasospasm, Intracranial | Intracranial Aneurysm | Heparin-induced Thrombocytopenia Type IIUnited States
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaUnknownRenal Failure | HemodialysisItaly
-
Azidus BrasilUnknownPrevention of Venous ThromboembolismBrazil
-
Christine RibicMcMaster University; LEO PharmaCompleted
-
The University of Texas Health Science Center at...WithdrawnThrombosis | Anticoagulants | Infant, PrematureUnited States
-
Regado Biosciences, Inc.CompletedAcute Coronary Syndrome (ACS)United States, Canada, Germany, France
-
Azidus BrasilSuspendedChronic Renal FailureBrazil
-
University of OklahomaRecruitingRecurrent Urinary Tract InfectionsUnited States
-
McMaster UniversityCompleted